Abstract
Neuroblastoma is the leading cause of cancer death in young children. Although treatment for neuroblastoma has improved, the 5-year survival rate of patients still remains less than half. Recent studies have indicated that bevacizumab, an anti-VEGF drug used in treatment of several other cancer types, may be effective for treating neuroblastoma as well. However, its effect on neuroblastoma has not been well characterized. While traditional experiments are costly and time-consuming, mathematical models are capable of simulating complex systems quickly and inexpensively. In this study, we present a model of vascular tumor growth of neuroblastoma IMR-32 that is complex enough to replicate experimental data across a range of tumor cell properties measured in a suite of in vitro and in vivo experiments. The model provides quantitative insight into tumor vasculature, predicting a linear relationship between vasculature and tumor volume. The tumor growth model was coupled with known pharmacokinetics and pharmacodynamics of the VEGF blocker bevacizumab to study its effect on neuroblastoma growth dynamics. The results of our model suggest that total administered bevacizumab concentration per week, as opposed to dosage regimen, is the major determining factor in tumor suppression. Our model also establishes an exponentially decreasing relationship between administered bevacizumab concentration and tumor growth rate.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ackermann S, Goeser F, Schulte JH, Schramm A, Ehemann V, Hero B, Eggert A, Berthold F, Fischer M (2011) Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma. Clin Cancer Res 17(4):731–741. https://doi.org/10.1158/1078-0432.CCR-10-1129
Alarcon T, Byrne H, Maini P, Panovska J (2005) 20 Mathematical modelling of angiogenesis and vascular adaptation. Stud Multidiscip 3(C):369–387. https://doi.org/10.1016/s1571-0831(06)80024-9
Alarcón T, Owen MR, Byrne HM, Maini PK (2006) Multiscale modelling of tumour growth and therapy: the influence of vessel normalisation on chemotherapy. Comput Math Methods Med. https://doi.org/10.1080/10273660600968994
Argyri KD, Dionysiou DD, Misichroni FD, Stamatakos GS (2016) Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data. Biol Direct 11(1):12. https://doi.org/10.1186/s13062-016-0114-9
Bäckman U, Christofferson R (2005) The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice. Pediatr Res 57(5 I):690–695. https://doi.org/10.1203/01.pdr.0000156508.68065.aa
Botchkina GI, Meistrell ME, Botchkina IL, Tracey KJ (1997) Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia. Mol Med 3(11):765–781. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2230243/
Brú A, Albertos S, Subiza JL, García-Asenjo JL, Brú I (2003) The universal dynamics of tumor growth. Biophys J 85(November):2948–2961. https://doi.org/10.1016/S0006-3495(03)74715-8
Byrne HM (2010) Dissecting cancer through mathematics: from the cell to the animal model. Nat Rev Cancer 10(3):221–230. https://doi.org/10.1038/nrc2808
Carlsson J, Nilsson K, Westermark B, Pontén J, Sundström C, Larsson E, Bergh J, Påhlman S, Busch C, Collins VP (1983) Formation and growth of multicellular spheroids of human origin. Int J Cancer 31(5):523–533. https://doi.org/10.1002/ijc.2910310502
De Bernardi B, Pianca C, Boni L, Brisigotti M, Carli M, Bagnulo S, Corciulo P, Mancini A, De Laurentis C, Di Tullio MT (1992) Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Italian Cooperative group on neuroblastoma. Cancer 70(6):1625–1633
De Mattei V, Flandoli F, Leocata M, Polito MC, Ricci C (2016) A mathematical model for growth of solid tumors and combination therapy with an application to colorectal cancer, 1–21. http://arxiv.org/abs/1607.08009
Demidenko E (2006) The assessment of tumour response to treatment. J R Stat Soc Ser C (Appl Stat) 55(3):365–377. http://www.jstor.org.dartmouth.idm.oclc.org/stable/4126391
Edmondson R, Broglie JJ, Adcock AF, Yang L (2014) Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol 12(4):207–218. https://doi.org/10.1089/adt.2014.573
Folkman J (1974) Tumor angiogenesis 11 this work was supported by a grant from the National Cancer Institute (No. 1 RO1 CA 14019–01), a grant from the American Cancer Society (No. DT-2A), and gifts from Alza Corporation, Merck Co., and Mr. Morton Bank. Adv Cancer Res 19:331–358. https://doi.org/10.1016/S0065-230X(08)60058-5
Folkman J, Hochberg M (1973) Self-regulation of growth in three dimensions. J Exp Med 138(4):745–753. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2180571/
Folkman J, Cole P, Zimmerman S (1966) Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 164(3):491–502. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1477290/
Freyer P (1988) Role of necrosis in regulating the growth saturation of multicellular spheroids. Cancer Res 48(9):2432–2439
Genentech Inc. (2017) Avastin prescribing information. Genentech, Inc.
Gerber H-P, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65(3):671–680
Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L (1999) Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 59(19):4770–4775
Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol Off J Am Soc Clin Oncol 23(5):1011–1027. https://doi.org/10.1200/jco.2005.06.081
Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 23(15):3502–3508. https://doi.org/10.1200/jco.2005.10.017
Jing Y, Ma N, Fan T, Wang C, Xinxin B, Jiang G, Li R et al (2011) Tumor necrosis factor-alpha promotes tumor growth by inducing vascular endothelial growth factor. Cancer Investig 29(7):485–493. https://doi.org/10.3109/07357907.2011.597812
Keating GM (2014) Bevacizumab: a review of its use in advanced cancer. Drugs 74(16):1891–1925. https://doi.org/10.1007/s40265-014-0302-9
Kim JB (2005) Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol 15(5):365–377. https://doi.org/10.1016/j.semcancer.2005.05.002
Kumar A, Fan D, DiPette DJ, Singh US (2014) Sparstolonin B, a novel plant derived compound, arrests cell cycle and induces apoptosis in N-myc amplified and N-myc nonamplified neuroblastoma cells. PLoS ONE 9(5):e96343. https://doi.org/10.1371/journal.pone.0096343
Landry J, Freyer JP, Sutherland RM (1982) A model for the growth of multicellular spheroids. Cell Tissue Kinet 15(6):585–594
Lee SH, Jeong D, Han Y-S, Baek MJ (2015) Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res. https://doi.org/10.4174/astr.2015.89.1.1
Leeuwenberg JFM, van Tits LJH, Jeunhomme TMAA, Buurman WA (1995) Evidence for exclusive role in signalling of tumour necrosis factor p55 receptor and a potentiating function of p75 receptor on human endothelial cells. Cytokine 7(5):457–462. https://doi.org/10.1006/cyto.1995.0062
Lignet F, Benzekry S, Wilson S, Billy F, Saut O, Tod M, You B et al (2013) Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice. J Theor Biol 320(March):86–99. https://doi.org/10.1016/j.jtbi.2012.12.013
Lu J-F, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J (2008a) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. https://doi.org/10.1007/s00280-007-0664-8
Lu J-F, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J (2008b) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62(5):779–786. https://doi.org/10.1007/s00280-007-0664-8
Lv C, Shuodong W, Zheng D, Yuli W, Yao D, Xiaopeng Yu (2013) The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials. Cancer Biother Radiopharm 28(7):501–509. https://doi.org/10.1089/cbr.2012.1458
Marušić M, Bajzer Ž, Freyer JP, Vuk-Pavlović S (1994) Analysis of growth of multicellular tumour spheroids by mathematical models. Cell Prolif 27(2):73–94. https://doi.org/10.1111/j.1365-2184.1994.tb01407.x
Menchón SA, Condat CA (2008) Cancer growth: predictions of a realistic model. Phys Rev E Stat Nonlinear Soft Matter Phys 78(2 Pt 1):22901. https://doi.org/10.1103/physreve.78.022901
Menchón SA, Condat CA (2009) Modeling tumor cell shedding. Eur Biophys J 38(4):479–485. https://doi.org/10.1007/s00249-008-0398-5
Mollard S, Ciccolini J, Imbs D-C, El Cheikh R, Barbolosi D, Benzekry S (2017) Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis. Oncotarget 8(14):23087–23098. https://doi.org/10.18632/oncotarget.15484
NC3Rs (2017) Mouse: decision tree for blood sampling | NC3Rs. https://www.nc3rs.org.uk/mouse-decision-tree-blood-sampling. Accessed 1 Jan 2017
Piantadosi S (1985) A model of growth with first-order birth and death rates. Comput Biomed Res Int J 18(3):220–232
Pinho STR, Bacelar FS, Andrade RFS, Freedman HI (2013) A mathematical model for the effect of anti-angiogenic therapy in the treatment of cancer tumours by chemotherapy. Nonlinear Anal Real World Appl 14(1):815–828. https://doi.org/10.1016/j.nonrwa.2012.07.034
Poleszczuk J, Hahnfeldt P, Enderling H (2015) Therapeutic implications from sensitivity analysis of tumor angiogenesis models. PLoS ONE 10(3):e0120007. https://doi.org/10.1371/journal.pone.0120007
R Development Core Team (2011) R: a language and environment for statistical computing, vol 1. R Foundation for Statistical Computing, Vienna. https://doi.org/10.1007/978-3-540-74686-7
Sasi SP, Yan X, Enderling H, Park D, Gilbert H-Y, Curry C, Coleman C et al (2012) Breaking the ‘harmony’ of TNF-alpha signaling for cancer Treatment. Oncogene 31(37):4117–4127. https://doi.org/10.1038/onc.2011.567
Seeger RC, Rayner SA, Banerjee A, Benedict WF, Chung H, Laug WE, Neustein HB (1977) Morphology, growth, chromosomal pattern, and fibrinolytic activity of two new human neuroblastoma cell lines. Cancer Res 37(5):1364–1371
Segerström L, Fuchs D, Bäckman U, Holmquist K, Christofferson R, Azarbayjani F (2006) The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr Res 60(5):576–581. https://doi.org/10.1203/01.pdr.0000242494.94000.52
Sherar MD, Noss MB, Foster FS (1987) Ultrasound backscatter microscopy images the internal structure of living tumour spheroids. Nature 330(6147):493–495. https://doi.org/10.1038/330493a0
Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359(6398):843–845. https://doi.org/10.1038/359843a0
Sims TL, Williams RF, Ng CY, Rosati SF, Spence Y, Davidoff AM (2008) Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease. Surgery 144(2):269–275. https://doi.org/10.1016/j.surg.2008.04.009
Sweeney CJ, Miller KD, Sledge GW Jr (2003) Resistance in the anti-angiogenic era: nay-saying or a word of caution? Trends Mol Med 9(1):24–29
Szlosarek PW, Balkwill FR (2003) Tumour necrosis factor [alpha]: a potential target for the therapy of solid tumours. Lancet Oncol 4(9):565
Taconic Bioscience (2013) NCr nude mice | athymic mouse model. https://www.taconic.com/mouse-model/ncr-nude
Takagi A, Watanabe M, Ishii Y, Morita J, Hirokawa Y, Matsuzaki T, Shiraishi T (2007) Three-dimensional cellular spheroid formation provides human prostate tumor cells with tissue-like features. Anticancer Res 27(1A):45–53
Tan PH, Chan C, Xue SA, Dong R, Ananthesayanan B, Manunta M, Kerouedan C et al (2004) Phenotypic and functional differences between human saphenous vein (HSVEC) and umbilical vein (HUVEC) endothelial cells. Atherosclerosis 173(2):171–183. https://doi.org/10.1016/j.atherosclerosis.2003.12.011
Tang L, Van De Ven AL, Guo D, Andasari V, Cristini V, Li KC, Zhou X (2014) Computational modeling of 3D tumor growth and angiogenesis for chemotherapy evaluation. PLoS ONE 9(1):1–12. https://doi.org/10.1371/journal.pone.0083962
The Mathworks Inc. (2016) MATLAB—mathworks. www.mathworks.com/products/matlab. doi: 2016-11-26
U.S. Cancer Statistics Working (2017) United States cancer statistics: 1999–2014 incidence and mortality web-based report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, no. 888: 6348. www.cdc.gov/uscs
Wallace DI, Guo X (2013) Properties of tumor spheroid growth exhibited by simple mathematical models. Front Oncol 3(March):51. https://doi.org/10.3389/fonc.2013.00051
Wallace DI, Dunham A, Chen PX, Chen M, Huynh M, Rheingold E, Prosper O (2016) A model for spheroid versus monolayer response of SK-N-SH neuroblastoma cells to treatment with 15-deoxy-PGJ 2. Comput Math Methods Med 2016:1–11. https://doi.org/10.1155/2016/3628124
Wassberg E, Hedborg F, Sköldenberg E, Stridsberg M, Christofferson R (1999) Inhibition of angiogenesis induces chromaffin differentiation and apoptosis in neuroblastoma. Am J Pathol 154(2):395–403. https://doi.org/10.1016/S0002-9440(10)65286-8
Wu F, Tamhane M, Morris M (2012) Pharmacokinetics, lymph node uptake, and mechanistic PK model of near-infrared dye-labeled bevacizumab after IV and SC administration in mice. AAPS J 14(2):252–261. https://doi.org/10.1208/s12248-012-9342-9
Acknowledgements
This work was supported by the Women in Science Program, Sophomore Science Scholars Program, James O. Freedman Presidential Scholar, and Undergraduate Leave Term Research Grant to Yixuan He from the Office of Undergraduate Research at Dartmouth College.
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
He, Y., Kodali, A. & Wallace, D.I. Predictive Modeling of Neuroblastoma Growth Dynamics in Xenograft Model After Bevacizumab Anti-VEGF Therapy. Bull Math Biol 80, 2026–2048 (2018). https://doi.org/10.1007/s11538-018-0441-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11538-018-0441-3